Literature DB >> 8252582

Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells.

M Neusser1, M Tepel, W Zidek.   

Abstract

OBJECTIVES: The underlying pathophysiological mechanism leading to raised blood pressure after treatment with erythropoietin is a point of much discussion. Direct vasopressor effects of erythropoietin have been shown recently. The aim was to determine whether erythropoietin effects cytosolic free calcium concentration ([Ca2+]i in vascular smooth muscle cells.
METHODS: The effect of erythropoietin on ([Ca2+]i was measured with the fluorescent dye fura2 in cultured vascular smooth muscle cells from Wistar Kyoto rats.
RESULTS: Mean resting [Ca2+]i was 90.8(SEM 5.6) nM (n = 32). Addition of erythropoietin at concentrations of 100 U.ml-1 and 250 U.ml-1 increased [Ca2+]i to 112.3(5.0) nM (n = 23, p < 0.05) and 128.4(4.0) nM (n = 10, p < 0.01), respectively. Preincubation with erythropoietin caused a dose dependent increase in angiotensin II induced changes of [Ca2+]i in vascular smooth muscle cells.
CONCLUSIONS: One mechanism of erythropoietin induced hypertension may be an increase in [Ca2+]i in vascular smooth muscle cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8252582     DOI: 10.1093/cvr/27.7.1233

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  8 in total

1.  JAK2/STAT3/BMP-2 axis and NF-κB pathway are involved in erythropoietin-induced calcification in rat vascular smooth muscle cells.

Authors:  Jin He; Xiaoyi Zhong; Lin Zhao; Hua Gan
Journal:  Clin Exp Nephrol       Date:  2018-11-07       Impact factor: 2.801

2.  Effect of 1-week treatment with erythropoietin on the vascular endothelial function in anaesthetized rabbits.

Authors:  K Noguchi; S Yamashiro; T Matsuzaki; M Sakanashi; J Nakasone; K Miyagi; M Sakanashi
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

Review 3.  Cardiovascular effects of erythropoietin an update.

Authors:  Anantha Vijay R Santhanam; Livius V d'Uscio; Zvonimir S Katusic
Journal:  Adv Pharmacol       Date:  2010

4.  Recombinant human erythropoietin suppresses endothelial cell apoptosis and reduces the ratio of Bax to Bcl-2 proteins in the aortas of apolipoprotein E-deficient mice.

Authors:  Jeffrey S Warren; Ying Zhao; Raymond Yung; Anjali Desai
Journal:  J Cardiovasc Pharmacol       Date:  2011-04       Impact factor: 3.105

5.  Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities.

Authors:  Thomas R Coleman; Christof Westenfelder; Florian E Tögel; Ying Yang; Zhuma Hu; Leanne Swenson; Henri G D Leuvenink; Rutger J Ploeg; Livius V d'Uscio; Zvonimir S Katusic; Pietro Ghezzi; Adriana Zanetti; Kenneth Kaushansky; Norma E Fox; Anthony Cerami; Michael Brines
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

6.  Effect of recombinant erythropoietin on anemia and orthostatic hypotension in primary autonomic failure.

Authors:  R Perera; L Isola; H Kaufmann
Journal:  Clin Auton Res       Date:  1995-09       Impact factor: 4.435

Review 7.  Bench to bedside: A role for erythropoietin in sepsis.

Authors:  Andrew P Walden; J Duncan Young; Edward Sharples
Journal:  Crit Care       Date:  2010-08-06       Impact factor: 9.097

8.  Erythropoietin improves skeletal muscle microcirculation and tissue bioenergetics in a mouse sepsis model.

Authors:  Raymond Kao; Anargyros Xenocostas; Tao Rui; Pei Yu; Weixiong Huang; James Rose; Claudio M Martin
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.